Showing 116 results
-
Media Release /Scemblix provides a new option for chronic myeloid leukemia (CML) patients who have had two or more previous tyrosine kinase inhibitor (TKI) treatments1 New mechanism of action with Scemblix…
-
Media Release /Novel mechanism of action of PLUVICTO™ binds to target PSMA-positive cancer cells, delivering radiation treatment directly to those cells and nearby cells1 Prostate cancer is the most diagnosed…
-
Media Release /Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy. 1,2 While wet age-…
-
Media Release /Kesimpta® is the first and only B-cell therapy for RRMS that can be administered by patients in the safety and convenience of their home Kesimpta® delivers superior efficacy with a favourable…
-
Media Release /Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer Dorval, Quebec, June 8,…
-
Media Release /Open feedback by Novartis associates contributed to coveted Canadian employer recognition Novartis ranked among the companies with the highest levels of trust and most inclusive cultures in the…
-
Story /Novartis associates in Canada are working from home or at our essential facilities so they can continue to serve patients.
-
Story /By Christian Macher, Country President
-
Story / -
Media Release /Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell…
